Bloodstream infections in haematology: Risks and new challenges for prevention

Blood Reviews

Volumn 23, Issue 3, 2009, Pages 113-122

  Worth, Leon J ^a,b   Slavin, Monica A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Bacteraemia; Bloodstream infection; Central venous catheter; Fungaemia; Haematology; Prevention; Risk

Indexed keywords

ALCOHOL; ALEMTUZUMAB; ANTACID AGENT; ANTIINFECTIVE AGENT; CARBAPENEM; CEPHALOSPORIN; COTRIMOXAZOLE; CYTARABINE; ECHINOCANDIN; FLUCONAZOLE; FLUDARABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; METRONIDAZOLE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABSCESS; ADJUVANT THERAPY; ADVERSE OUTCOME; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CANDIDEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; ELECTRIC POTENTIAL; ENVIRONMENTAL FACTOR; FEBRILE NEUTROPENIA; FLORA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTE; HEALTH CARE; HEMATOLOGY; HOSPITALIZATION; HOST; HOST RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION CONTROL; INTRAVENOUS CATHETER; LYMPHOCYTOPENIA; MORBIDITY; MORTALITY; MYCOSIS; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING;

BACTEREMIA; BACTERIA; FUNGEMIA; FUNGI; HUMANS; INCIDENCE; INFECTION CONTROL; RISK FACTORS;

EID: 63449138021     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.10.003     Document Type: Article

References (180)

1. Cherif H., Kronvall G., Bjorkholm M., and Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4 (2003) 420-426
2. Del Giudice I., and Foa R. New therapies in onco-hematology and new infectious risk factors. Rev Clin Exp Hematol 9 (2005) E1
3. Thursky K.A., Worth L.J., Seymour J.F., Miles Prince H., and Slavin M.A. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 132 (2006) 3-12
4. Yuen K.Y., Woo P.C., Hui C.H., et al. Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. Bone Marrow Transplant 21 (1998) 1137-1143
5. Rahal J.J. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 Suppl. 2 (2006) S95-S99
6. Klastersky J. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Cancer Treat Rev 29 (2003) 431-440
7. Viscoli C., and Castagnola E. Treatment of febrile neutropenia: what is new?. Curr Opin Infect Dis 15 (2002) 377-382
8. Bodey G.P., and Rolston K.V. Management of fever in neutropenic patients. J Infect Chemother 7 (2001) 1-9
9. Slavin M.A., Szer J., Grigg A.P., et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 34 (2004) 192-200
10. Morra E., Nosari A., and Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 41 (1999) 145-151
11. Potter M. New anti-cancer therapies, new opportunities for infection. Curr Opin Infect Dis 12 (1999) 359-363
12. O'Brien S.N., Blijlevens N.M., Mahfouz T.H., and Anaissie E.J. Infections in patients with hematological cancer: recent developments. Hematology (Am Soc Hematol Educ Program) (2003) 438-472
13. Blijlevens N.M., Donnelly J.P., and de Pauw B.E. Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. Clin Microbiol Infect 7 Suppl. 4 (2001) 47-52
14. Gonzalez-Barca E., Carratala J., Mykietiuk A., Fernandez-Sevilla A., and Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 20 (2001) 117-119
15. Axelrod P.I., Lorber B., and Vonderheid E.C. Infections complicating mycosis fungoides and Sezary syndrome. Jama 267 (1992) 1354-1358
16. Raad I., Narro J., Khan A., Tarrand J., Vartivarian S., and Bodey G.P. Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients. Eur J Clin Microbiol Infect Dis 11 (1992) 675-682
17. Skov R., Gottschau A., Skinhoj P., Frimodt-Moller N., Rosdahl V.T., and Espersen F. Staphylococcus aureus bacteremia: a 14-year nationwide study in hematological patients with malignant disease or agranulocytosis. Scand J Infect Dis 27 (1995) 563-568
18. Ghanem G.A., Boktour M., Warneke C., et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 86 (2007) 54-60
19. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32 (2001) 1249-1272
20. Venditti M., Falcone M., Micozzi A., et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies: a retrospective case-control study. Haematologica 88 (2003) 923-930
21. Espersen F., Frimodt-Moller N., Rosdahl V.T., Jessen O., Faber V., and Rosendal K. Staphylococcus aureus bacteremia in patients with hematological malignancies and/or agranulocytosis. Acta Med Scand 222 (1987) 465-470
22. Favre B., Hugonnet S., Correa L., Sax H., Rohner P., and Pittet D. Nosocomial bacteremia: clinical significance of a single blood culture positive for coagulase-negative staphylococci. Infect Control Hosp Epidemiol 26 (2005) 697-702
23. Elishoov H., Or R., Strauss N., and Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine (Baltimore) 77 (1998) 83-101
24. Beekmann S.E., Diekema D.J., and Doern G.V. Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. Infect Control Hosp Epidemiol 26 (2005) 559-566
25. Ortega M., Rovira M., Almela M., et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol 84 (2005) 40-46
26. Velasco E., Byington R., Martins C.S., Schirmer M., Dias L.C., and Goncalves V.M. Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect 10 (2004) 542-549
27. Ninin E., Caroff N., Espaze E., et al. Assessment of ica operon carriage and biofilm production in Staphylococcus epidermidis isolates causing bacteraemia in bone marrow transplant recipients. Clin Microbiol Infect 12 (2006) 446-452
28. Engelhard D., Elishoov H., Strauss N., et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. Transplantation 61 (1996) 430-434
29. Falcone M., Micozzi A., Pompeo M.E., et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother 16 (2004) 540-548
30. Christensen G.D., Bisno A.L., Parisi J.T., McLaughlin B., Hester M.G., and Luther R.W. Nosocomial septicemia due to multiply antibiotic-resistant Staphylococcus epidermidis. Ann Intern Med 96 (1982) 1-10
31. Ashour H.M., and el-Sharif A. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients. J Clin Oncol 25 (2007) 5763-5769
32. Wroblewska M.M., Marchel H., and Luczak M. Multidrug resistance in bacterial isolates from blood cultures of haematology patients. Int J Antimicrob Agents 19 (2002) 237-240
33. Pagano L., Tacconelli E., Tumbarello M., et al. Teicoplanin-resistant coagulase-negative staphylococcal bacteraemia in patients with haematological malignancies: a problem of increasing importance. J Antimicrob Chemother 40 (1997) 738-740
34. Kumashi P., Girgawy E., Tarrand J.J., Rolston K.V., Raad I.I., and Safdar A. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine (Baltimore) 84 (2005) 303-312
35. Engelhard D., Cordonnier C., Shaw P.J., et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European bone marrow transplantation survey. Br J Haematol 117 (2002) 444-450
36. Kulkarni S., Powles R., Treleaven J., et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95 (2000) 3683-3686
37. Engelhard D., Elishoov H., Or R., et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 16 (1995) 565-570
38. Richard P., Amador Del Valle G., Moreau P., et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 345 (1995) 1607-1609
39. Elting L.S., Bodey G.P., and Keefe B.H. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14 (1992) 1201-1207
40. Tunkel A.R., and Sepkowitz K.A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 34 (2002) 1524-1529
41. Bostrom B., and Weisdorf D. Mucositis and alpha-streptococcal sepsis in bone marrow transplant recipients. Lancet 1 (1984) 1120-1121
42. Ringden O., Heimdahl A., Lonnqvist B., Malmborg A.S., and Wilczek H. Decreased incidence of viridans streptococcal septicaemia in allogeneic bone marrow transplant recipients after the introduction of acyclovir. Lancet 1 (1984) 744
43. Zaas A.K., Song X., Tucker P., and Perl T.M. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 35 (2002) 1139-1146
44. Kuehnert M.J., Jernigan J.A., Pullen A.L., Rimland D., and Jarvis W.R. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol 20 (1999) 660-663
45. Worth L.J., Thursky K.A., Seymour J.F., and Slavin M.A. Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol (2007)
46. Kobayashi K., Kami M., Ikeda M., et al. Fulminant septicemia caused by Bacillus cereus following reduced-intensity umbilical cord blood transplantation. Haematologica 90 (2005) ECR06
47. Kotiranta A., Lounatmaa K., and Haapasalo M. Epidemiology and pathogenesis of Bacillus cereus infections. Microbes Infect 2 (2000) 189-198
48. Sakai C., Iuchi T., Ishii A., Kumagai K., and Takagi T. Bacillus cereus brain abscesses occurring in a severely neutropenic patient: successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage. Intern Med 40 (2001) 654-657
49. Ozkocaman V., Ozcelik T., Ali R., et al. Bacillus spp. among hospitalized patients with haematological malignancies: clinical features, epidemics and outcomes. J Hosp Infect 64 (2006) 169-176
50. Riebel W., Frantz N., Adelstein D., and Spagnuolo P.J. Corynebacterium JK: a cause of nosocomial device-related infection. Rev Infect Dis 8 (1986) 42-49
51. Quinn J.P., Arnow P.M., Weil D., and Rosenbluth J. Outbreak of JK diphtheroid infections associated with environmental contamination. J Clin Microbiol 19 (1984) 668-671
52. Telander B., Lerner R., Palmblad J., and Ringertz O. Corynebacterium group JK in a hematological ward: infections, colonization and environmental contamination. Scand J Infect Dis 20 (1988) 55-61
53. van der Lelie H., Leverstein-Van Hall M., Mertens M., et al. Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and a systematic literature review. Scand J Infect Dis 27 (1995) 581-584
54. Anaissie E., Kontoyiannis D.P., Kantarjian H., Elting L., Robertson L.E., and Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 117 (1992) 466-469
55. Hequet O., de Jaureguiberry J.P., Jaubert D., Gisserot O., Muzellec Y., and Brisou P. Listeriosis after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 39 (1997) 89-91
56. Lee S.A., Raad I.I., Adachi J.A., and Han X.Y. Catheter-related bloodstream infection caused by Mycobacterium brumae. J Clin Microbiol 42 (2004) 5429-5431
57. Washer L.L., Riddell Jt., Rider J., and Chenoweth C.E. Mycobacterium neoaurum bloodstream infection: report of 4 cases and review of the literature. Clin Infect Dis 45 (2007) e10-e13
58. Levendoglu-Tugal O., Munoz J., Brudnicki A., Fevzi Ozkaynak M., Sandoval C., and Jayabose S. Infections due to nontuberculous mycobacteria in children with leukemia. Clin Infect Dis 27 (1998) 1227-1230
59. Raad I.I., Vartivarian S., Khan A., and Bodey G.P. Catheter-related infections caused by the Mycobacterium fortuitum complex: 15 cases and review. Rev Infect Dis 13 (1991) 1120-1125
60. Vianelli N., Giannini M.B., Quarti C., et al. Resolution of a Pseudomonas aeruginosa outbreak in a hematology unit with the use of disposable sterile water filters. Haematologica. 91 (2006) 983-985
61. Aumeran C., Paillard C., Robin F., et al. Pseudomonas aeruginosa and Pseudomonas putida outbreak associated with contaminated water outlets in an oncohaematology paediatric unit. J Hosp Infect 65 (2007) 47-53
62. Siebor E., Llanes C., Lafon I., et al. Presumed pseudobacteremia outbreak resulting from contamination of proportional disinfectant dispenser. Eur J Clin Microbiol Infect Dis 26 (2007) 195-198
63. Aubron C., Poirel L., Fortineau N., Nicolas P., Collet L., and Nordmann P. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 11 (2005) 254-259
64. Hachem R.Y., Chemaly R.F., Ahmar C.A., et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 51 (2007) 1905-1911
65. Ostronoff M., Ostronoff F., Sucupira A., et al. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis 10 (2006) 339-340
66. Lin Y.W., Adachi S., Watanabe K., Umeda K., and Nakahata T. Serial granulocyte transfusions as a treatment for sepsis due to multidrug-resistant Pseudomonas aeruginosa in a neutropenic patient. J Clin Microbiol 41 (2003) 4892-4893
67. Chan Y.H., Chong C.Y., Puthucheary J., and Loh T.F. Ecthyma gangrenosum: a manifestation of Pseudomonas sepsis in three paediatric patients. Singapore Med J 47 (2006) 1080-1083
68. Chatzinikolaou I., Abi-Said D., Bodey G.P., Rolston K.V., Tarrand J.J., and Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 160 (2000) 501-509
69. Grigis A., Goglio A., Parea M., Gnecchi F., Minetti B., and Barbui T. Nosocomial outbreak of severe Pseudomonas aeruginosa infections in haematological patients. Eur J Epidemiol 9 (1993) 390-395
70. Bodey G.P., Jadeja L., and Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145 (1985) 1621-1629
71. Rolston K.V. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 39 Suppl. 1 (2004) S44-S48
72. Micol J.B., de Botton S., Guieze R., et al. An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients. Haematologica 91 (2006) 1134-1138
73. Spanik S., Krupova I., Trupl J., et al. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case-controlled study. J Infect Chemother 5 (1999) 180-184
74. Krcmery Jr. V., Trup J., Kunova A., et al. Imipenen-resistant P. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome. Int J Clin Pharmacol Res 16 (1996) 43-49
75. Penzak S.R., Gubbins P.O., Stratton S.L., and Anaissie E.J. Investigation of an outbreak of gram-negative bacteremia among hematology-oncology outpatients. Infect Control Hosp Epidemiol 21 (2000) 597-599
76. Kang C.I., Kim S.H., Park W.B., et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11 (2005) 68-74
77. Ansari S.R., Hanna H., Hachem R., Jiang Y., Rolston K., and Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 109 (2007) 2615-2622
78. Apisarnthanarak A., Mayfield J.L., Garison T., et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 24 (2003) 269-274
79. Labarca J.A., Leber A.L., Kern V.L., et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis 30 (2000) 195-197
80. Lai C.H., Wong W.W., Chin C., et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect 12 (2006) 986-991
81. Funada H., and Matsuda T. Aeromonas bacteremia in patients with hematologic diseases. Intern Med 36 (1997) 171-174
82. Taneja N., Khurana S., Trehan A., Marwaha R.K., and Sharma M. An outbreak of hospital acquired diarrhea due to Aeromonas sobria. Indian Pediatr 41 (2004) 912-916
83. Wolff R.L., Wiseman S.L., and Kitchens C.S. Aeromonas hydrophila bacteremia in ambulatory immunocompromised hosts. Am J Med 68 (1980) 238-242
84. Harris R.L., Fainstein V., Elting L., Hopfer R.L., and Bodey G.P. Bacteremia caused by Aeromonas species in hospitalized cancer patients. Rev Infect Dis 7 (1985) 314-320
85. Tsai M.S., Kuo C.Y., Wang M.C., Wu H.C., Chien C.C., and Liu J.W. Clinical features and risk factors for mortality in Aeromonas bacteremic adults with hematologic malignancies. J Microbiol Immunol Infect 39 (2006) 150-154
86. Martino R., Santamaria A., Pericas R., Sureda A., and Brunet S. Acute rhabdomyolysis and myonecrosis complicating aeromonas bacteremia in neutropenic patients with hematologic malignancies: report of two cases. Haematologica 82 (1997) 692-694
87. Chen Y.H., Chen T.P., Lu P.L., et al. Salmonella choleraesuis bacteremia in southern Taiwan. Kaohsiung J Med Sci 15 (1999) 202-208
88. Delaloye J., Merlani G., Petignat C., et al. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?. Eur J Clin Microbiol Infect Dis 23 (2004) 751-758
89. Lark R.L., McNeil S.A., VanderHyde K., Noorani Z., Uberti J., and Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 33 (2001) 338-343
90. Coleman N., Speirs G., Khan J., Broadbent V., Wight D.G., and Warren R.E. Neutropenic enterocolitis associated with Clostridium tertium. J Clin Pathol 46 (1993) 180-183
91. Gosbell I.B., Johnson C.G., Newton P.J., and Jelfs J. Clostridium tertium bacteremia: 2 cases and review. Pathology 28 (1996) 70-73
92. Spanik S., Trupl J., Kunova A., et al. Bloodstream infections due to anaerobic bacteria in cancer patients: epidemiology, etiology, risk factors, clinical presentation and outcome of anaerobic bacteremia. Neoplasma 43 (1996) 235-238
93. Candoni A., Fili C., Trevisan R., Silvestri F., and Fanin R. Fusobacterium nucleatum: a rare cause of bacteremia in neutropenic patients with leukemia and lymphoma. Clin Microbiol Infect 9 (2003) 1112-1115
94. Slavin M.A., Grigg A.P., and Schwarer A.P. Fatal anerobic bacteremia after hematopoietic stem cell transplant. Leuk Lymphoma 45 (2004) 143-145
95. Bodey G.P., Rodriguez S., Fainstein V., and Elting L.S. Clostridial bacteremia in cancer patients. A 12-year experience. Cancer 67 (1991) 1928-1942
96. Pirrotta M.T., Bucalossi A., Forconi F., et al. Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia. Leuk Lymphoma 46 (2005) 793
97. Moses A.E., Hardan I., Simhon A., et al. Clostridium septicum bacteremia and diffuse spreading cellulitis of the head and neck in a leukemic patient. Rev Infect Dis 13 (1991) 525-527
98. Goodrich J.M., Reed E.C., Mori M., et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 164 (1991) 731-740
99. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000) 309-316
100. Pagano L., Antinori A., Ammassari A., et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes. Eur J Haematol 63 (1999) 77-85
101. Uzun O., Ascioglu S., Anaissie E.J., and Rex J.H. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 32 (2001) 1713-1717
102. Safdar A., Chaturvedi V., Cross E.W., et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 45 (2001) 2129-2133
103. Slavin M.A. The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 49 Suppl. 1 (2002) 3-6
104. Viscoli C., Girmenia C., Marinus A., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28 (1999) 1071-1079
105. Berenguer J., Rodriguez-Tudela J.L., Richard C., et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group. Medicine (Baltimore) 76 (1997) 256-265
106. Carreter de Granda M.E., Richard C., Conde E., et al. Endocarditis caused by Scedosporium prolificans after autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 20 (2001) 215-217
107. Boutati E.I., and Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 90 (1997) 999-1008
108. Howden B.P., Slavin M.A., Schwarer A.P., and Mijch A.M. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 22 (2003) 111-113
109. Alvarez M., Lopez Ponga B., Rayon C., et al. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol 33 (1995) 3290-3295
110. Tapia M., Richard C., Baro J., et al. Scedosporium inflatum infection in immunocompromised haematological patients. Br J Haematol 87 (1994) 212-214
111. Simarro E., Marin F., Morales A., Sanz E., Perez J., and Ruiz J. Fungemia due to Scedosporium prolificans: a description of two cases with fatal outcome. Clin Microbiol Infect 7 (2001) 645-647
112. Barbaric D., and Shaw P.J. Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol 37 (2001) 122-125
113. Jensen T.G., Gahrn-Hansen B., Arendrup M., and Bruun B. Fusarium fungaemia in immunocompromised patients. Clin Microbiol Infect 10 (2004) 499-501
114. Dignani M.C., and Anaissie E. Human fusariosis. Clin Microbiol Infect 10 Suppl. 1 (2004) 67-75
115. Musa M.O., Al Eisa A., Halim M., et al. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol 108 (2000) 544-548
116. Blazar B.R., Hurd D.D., Snover D.C., Alexander J.W., and McGlave P.B. Invasive Fusarium infections in bone marrow transplant recipients. Am J Med 77 (1984) 645-651
117. Elting L.S., Rubenstein E.B., Rolston K.V., and Bodey G.P. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25 (1997) 247-259
118. Klastersky J., Ameye L., Maertens J., et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents (2007)
119. Rolston K.V., Bodey G.P., and Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 45 (2007) 228-233
120. Safdar A., Malathum K., Rodriguez S.J., Husni R., and Rolston K.V. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer 100 (2004) 1531-1536
121. Norgaard M., Larsson H., Pedersen G., Schonheyder H.C., and Sorensen H.T. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect 12 (2006) 217-223
122. Krcmery V., Spanik S., Mrazova M., et al. Bacteremias caused by Escherichia coli in cancer patients - analysis of 65 episodes. Int J Infect Dis 6 (2002) 69-73
123. Spanik S., Trupl J., Kunova A., et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microbiol 46 (1997) 517-523
124. Raad I., Hachem R., Hanna H., et al. Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters. Eur J Clin Microbiol Infect Dis 26 (2007) 549-556
125. Gonzalez-Barca E., Fernandez-Sevilla A., Carratala J., et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis 18 (1999) 539-544
126. Guven G.S., Uzun O., Cakir B., Akova M., and Unal S. Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997-2001). Support Care Cancer 14 (2006) 52-55
127. Celebi H., Akan H., Akcaglayan E., Ustun C., and Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant 26 (2000) 211-214
128. Clemons M.J., Valle J.W., Harris M., Ellenbogen S., and Howell A. Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Clin Oncol (R Coll Radiol) 9 (1997) 172-175
129. Davila M.L. Neutropenic enterocolitis: current issues in diagnosis and management. Curr Infect Dis Rep 9 (2007) 116-120
130. Boddie Jr. A.W., and Bines S.D. Management of acute rectal problems in leukemic patients. J Surg Oncol 33 (1986) 53-56
131. Barnes S.G., Sattler F.R., and Ballard J.O. Perirectal infections in acute leukemia. Improved survival after incision and debridement. Ann Intern Med 100 (1984) 515-518
132. Kirby J.T., Fritsche T.R., and Jones R.N. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis 56 (2006) 75-82
133. Safdar A., Rodriguez G.H., Balakrishnan M., Tarrand J.J., and Rolston K.V. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis 25 (2006) 522-526
134. Funada H., Machi T., and Matsuda T. Changing patterns of blood culture isolates from patients with acute leukemia: a review of twenty years' experience. Kansenshogaku Zasshi 66 (1992) 1022-1029
135. Funada H., and Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. Intern Med 37 (1998) 1014-1018
136. Oppenheim B.A. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 41 Suppl. D (1998) 7-11
137. Zinner S.H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29 (1999) 490-494
138. Meunier F., Aoun M., and Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 14 Suppl. 1 (1992) S120-S125
139. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39 Suppl. 1 (2004) S25-S31
140. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 (2005) 977-987
141. Jugo J., Kennedy R., Crowe M.J., et al. Trends in bacteraemia on the haematology and oncology units of a UK tertiary referral hospital. J Hosp Infect 50 (2002) 48-55
142. Youssef S., Rodriguez G., Rolston K.V., Champlin R.E., Raad I.I., and Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore) 86 (2007) 69-77
143. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-713; 715; 717-627; quiz 729-633.
144. Antin J.H., Guinan E.C., Avigan D., et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11 (2005) 213-222
145. William B.M., Thawani N., Sae-Tia S., and Corazza G.R. Hyposplenism: a comprehensive review. Part II: clinical manifestations, diagnosis, and management. Hematology 12 (2007) 89-98
146. van der Velden A.M., Claessen A.M., van Velzen-Blad H., et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine 25 (2007) 8512-8517
147. Zielen S., Buhring I., Strnad N., Reichenbach J., and Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect Immun 68 (2000) 1435-1440
148. Mutnick A.H., Kirby J.T., and Jones R.N. CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy alliance for neutropenics and the control of emerging resistance. Ann Pharmacother 37 (2003) 47-56
149. Worth L.J., Slavin M.A., Brown G.V., and Black J. Catheter-related bloodstream infections in hematology: time for standardized surveillance?. Cancer 109 (2007) 1215-1226
150. Morrissey C.O., Bardy P.G., Slavin M.A., et al. Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Intern Med J 38 (2008) 477-495
151. Rolston K.V. Management of infections in the neutropenic patient. Annu Rev Med 55 (2004) 519-526
152. Kern W.V., Klose K., Jellen-Ritter A.S., et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24 (2005) 111-118
153. Reuter S., Kern W.V., Sigge A., et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 40 (2005) 1087-1093
154. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 171 (1995) 1545-1552
155. Laverdiere M., Rotstein C., Bow E.J., et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian fluconazole study. J Antimicrob Chemother 46 (2000) 1001-1008
156. Brion L.P., Uko S.E., and Goldman D.L. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 54 (2007) 521-529
157. Vos M.C., Endtz H.P., Horst-Kreft D., et al. Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures. J Clin Microbiol 44 (2006) 1111-1114
158. Coia J.E., Duckworth G.J., Edwards D.I., et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 63 Suppl. 1 (2006) S1-S44
159. Sample M.L., Gravel D., Oxley C., Toye B., Garber G., and Ramotar K. An outbreak of vancomycin-resistant enterococci in a hematology-oncology unit: control by patient cohorting and terminal cleaning of the environment. Infect Control Hosp Epidemiol 23 (2002) 468-470
160. Shaw B.E., Boswell T., Byrne J.L., Yates C., and Russell N.H. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant 39 (2007) 623-629
161. Gillespie T.A., Johnson P.R., Notman A.W., Coia J.E., and Hanson M.F. Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit. Clin Microbiol Infect 6 (2000) 125-130
162. Bradley S.J., Wilson A.L., Allen M.C., Sher H.A., Goldstone A.H., and Scott G.M. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 43 (1999) 261-266
163. Rolston K.V. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40 Suppl. 4 (2005) S246-S252
164. Price T.H. Granulocyte transfusion: current status. Semin Hematol 44 (2007) 15-23
165. Weinstock D.M., Conlon M., Iovino C., et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13 (2007) 615-621
166. Avery R., Kalaycio M., Pohlman B., et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 35 (2005) 497-499
167. Ziglam H.M., Gelly K.J., and Olver W.J. A survey of the antibiotic treatment of febrile neutropenia in haematology units in the United Kingdom. Clin Lab Haematol 27 (2005) 374-378
168. Jaksic B., Martinelli G., Perez-Oteyza J., Hartman C.S., Leonard L.B., and Tack K.J. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42 (2006) 597-607
169. Chow A.W., Jewesson P.J., Kureishi A., and Phillips G.L. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol 54 Suppl. (1993) 18-24
170. Hanna H., Benjamin R., Chatzinikolaou I., et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 22 (2004) 3163-3171
171. Dannenberg C., Bierbach U., Rothe A., Beer J., and Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol 25 (2003) 616-621
172. Safdar N., and Maki D.G. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 43 (2006) 474-484
173. Schuttrumpf S., Binder L., Hagemann T., Berkovic D., Trumper L., and Binder C. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?. Ann Hematol 82 (2003) 98-103
174. Schuttrumpf S., Binder L., Hagemann T., Berkovic D., Trumper L., and Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 43 (2006) 468-473
175. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1 → 3) beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 41 (2005) 654-659
176. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39 (2004) 199-205
177. Obayashi T., Yoshida M., Mori T., et al. Plasma (1 → 3)-beta-d-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345 (1995) 17-20
178. Cordonnier C., Herbrecht R., Buzyn A., et al. Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica 90 (2005) 1102-1109
179. Ramzi J., Mohamed Z., Yosr B., et al. Predictive factors of septic shock and mortality in neutropenic patients. Hematology (2007) 1
180. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 (2000) 3038-3051